Clinical trials: SARS-CoV Infection
Upper Respiratory Infection
BD Veritor™ At-Home and BD Veritor™ Professional
The BD Veritor™ System is a rapid test that is testing for both COVID-19 and for Influenza This study will try to determine if the BD Veritor™ system can assist in the diagnosis of someone who has upper respiratory infection…
- Trial name
- NCT05352581
- Testing
- BD Veritor At-Home, BD Veritor Professional
- Where
- 17 sites in United States, Australia and 1 more
- Volunteers
- 1,146 people
- Sponsor
- Becton, Dickinson and Company
Covid-19
Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease
Two recent studies have suggested that in patients with Covid19, treatment with hydroxychloroquine may shorten the duration of symptoms and improve viral clearance, an effect that appears most pronounced when combined with…
- Trial name
- NCT04358081
- Testing
- HCQ, HCQ+AZT
- Where
- 7 sites in United States
- Volunteers
- 20 people
- Sponsor
- Novartis Pharmaceuticals
Covid19, SARS-CoV Infection
Imaging Immune Activation in COVID-19
This is a single center, single arm exploratory imaging study involving up to two intravenous microdoses of [18F]F-AraG (the second tracer dose is optional) followed by whole-body PET-CT imaging in participants with convalescent…
- Trial name
- NCT04815096
- Testing
- [18F]F-AraG (2'-deoxy-2'-fluoro-9-β-D-arabinofuranosylguanine)
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- CellSight Technologies, Inc.
COVID-19, Coronavirus
A Study to Assess Pulsed Inhaled Nitric Oxide vs Placebo in Subjects With Mild or Moderate COVID-19
A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of pulsed inhaled iNO compared to placebo in subjects with COVID-19.
- Conditions
- COVID-19, Coronavirus, Coronavirus Infection
- Trial name
- COViNOX (NCT04421508)
- Testing
- INOpulse
- Where
- 17 sites in United States
- Volunteers
- 191 people
- Sponsor
- Bellerophon Pulse Technologies
COVID-19 (Coronavirus Disease 2019)
A US Study to Look at Loss of Work and Healthcare Costs for People Affected With Mild-to-moderate COVID 19 Who Have High Chances of the Disease Becoming Severe
The purpose of this study is to understand how COVID-19 affects people's ability to work and to calculate the costs associated with loss of work.
- Trial name
- NCT07072793
- Testing
- nirmatrelvir-ritonavir
- Where
- United States
- Volunteers
- 131,005 people
- Sponsor
- Pfizer
SARS-CoV, SARS-CoV-2
Study of VXCO-100, a SARS-CoV Candidate Vaccine, in Adults in the Republic of South Africa
The purpose of this study is to evaluate the safety and immunogenicity of ascending dose levels of VXCO-100 in adults.
- Trial name
- NCT05938075
- Testing
- VXCO-100, COVID-19 mRNA vaccine
- Where
- 2 sites in South Africa
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- Vaccine Company, Inc, a wholly owned subsidiary of Eli Lilly and Company
COVID-19, Coronavirus Infections
Safety, Tolerability, and Immunogenicity of Trivalent Coronavirus Vaccine Candidate VBI-2901a
VBI-2901a is an investigational vaccine candidate that uses enveloped virus-like particles (eVLPs) to express the spike proteins of three coronaviruses: SARS-CoV-2 (the virus that causes COVID-19 disease), SARS-CoV-1 and…
- Trial name
- NCT05548439
- Testing
- VBI-2901a
- Where
- 7 sites in Canada
- Volunteers
- 103 people, healthy volunteers welcome
- Sponsor
- VBI Vaccines Inc.
Disease Caused by Severe Acute Respiratory Syndrome Coronavirus 2 (Disorder)
A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of Inhaled MBS-COV (SNS812) in Healthy Participants
A Phase I, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of Inhaled MBS-COV in Healthy Participants
- Trial name
- NCT05677893
- Testing
- MBS-COV
- Where
- United States
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Oneness Biotech Co., Ltd.
Infections, Respiratory, Virus Diseases
A Trial Investigating the Safety and Effects of Four BNT162 Vaccines Against COVID-19 in Healthy and Immunocompromised Adults
Originally, the study was planned to include two parts, i.e., Part A and Part B, however Part B was cancelled due to changes in the overall clinical development plan.
- Conditions
- Infections, Respiratory, Virus Diseases, Infection Viral, Vaccine Adverse Reaction
- Trial name
- NCT04380701
- Testing
- BNT162a1, BNT162b1, BNT162b2
- Where
- 5 sites in Germany
- Volunteers
- 512 people, healthy volunteers welcome
- Sponsor
- BioNTech SE
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV 2 Infection), COVID-19
SUNRISE-3: Efficacy and Safety of Bemnifosbuvir in High-Risk Outpatients With COVID-19
The purpose of the study is to evaluate whether bemnifosbuvir (BEM) is effective and safe in adults with COVID-19 who do not need to be in the hospital but who are at high risk for progression to severe disease.
- Trial name
- NCT05629962
- Testing
- Bemnifosbuvir (BEM)
- Where
- 263 sites in United States, Argentina and 17 more
- Volunteers
- 2,285 people
- Sponsor
- Atea Pharmaceuticals, Inc.
Covid19, Corona Virus Infection
Umbilical Cord Lining Stem Cells (ULSC) in Patients With COVID-19 ARDS
ULSC-CV-01 is a clinical trial that comprises both Phase 1 and Phase 2a, which will be conducted sequentially. This trial will evaluate the safety and potential efficacy of allogeneic Umbilical Cord Lining Stem Cells (ULSC)…
- Conditions
- Covid19, Corona Virus Infection, SARS-CoV Infection, ARDS
- Trial name
- ULSC (NCT04494386)
- Testing
- Umbilical Cord Lining Stem Cells (ULSC)
- Where
- 2 sites in United States
- Volunteers
- 17 people
- Sponsor
- Restem, LLC.
SARS CoV 2 Infection
The Efficacy and Safety of BioBlock® Intranasally Administered Virus-Neutralizing Bovine Colostrum Nasal Spray in Preventing of COVID-19 (Coronavirus Disease-19) Infection in Healthy Volunteer Individuals
This is a proof-of-concept double-blind cluster randomized (1:1) parallel study. The randomization unit is healthy volunteers who have no symptoms of COVID-19 at the start of the study and have not been infected with the…
- Trial name
- NCT05552950
- Testing
- BioBlock® antiviral nasal spray
- Where
- Estonia
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Chemi-Pharm AS
SARS-CoV Infection
Safety and Immunogenicity of an Intranasal SARS-CoV-2 Vaccine (BBV154) for COVID-19
The study is designed to evaluate the safety, reactogenicity, and immunogenicity of three groups of healthy volunteers who receive either intranasal single dose (vaccine on Day 0 and placebo on Day 28) or two-dose (vaccine on Day…
- Trial name
- NCT04751682
- Testing
- BBV154 Vaccine
- Where
- 4 sites in India
- Volunteers
- 175 people, healthy volunteers welcome
- Sponsor
- Bharat Biotech International Limited
SARS CoV 2 Infection
A Phase IIb/III Clinical Trial to Assess Safety and Immunogenicity of a COVID-19 Vaccine Booster Dose in Immunosupressed Adults.
A phase IIb/III, open label, single arm, multi-centre, trial to assess the immunogenicity and safety of an additional dose vaccination with a recombinant protein RBD fusion heterodimer candidate (PHH-1V) against SARS-CoV-2, in…
- Trial name
- NCT05303402
- Testing
- PHH-1V
- Where
- 6 sites in Spain, Turkey (Türkiye)
- Volunteers
- 241 people
- Sponsor
- Hipra Scientific, S.L.U
SARS-CoV 2, Infection
GLS-1200 Topical Nasal Spray to Prevent SARS-CoV-2 Infection (COVID-19)
This clinical trial will evaluate the safety, tolerability and effectiveness of topical GLS-1200 nasal spray to reduce the incidence of confirmed, symptomatic SARS-CoV-2 infection.
- Trial name
- NCT04408183
- Testing
- GLS-1200
- Where
- 3 sites in United States
- Volunteers
- 184 people, healthy volunteers welcome
- Sponsor
- GeneOne Life Science, Inc.
COVID-19, SARS CoV 2 Infection
To Evaluate the Safety, Efficacy,and Pharmacokinetics of Orally Administered Prolectin-M
ProLectin M is an orally administered polysaccharide. Polysaccharides competitively bind to the N-terminal tail of human galectin-3 through a proline isomerization [10].
- Trial name
- NCT05733780
- Testing
- Prolectin-M
- Volunteers
- 40 people
- Sponsor
- Bioxytran Inc.
Coronavirus Infections, SARS-CoV 2
Use of Hydroxychloroquine Alone or Associated for Inpatients With SARS-CoV2 Virus (COVID-19)
The Severe Acute Respiratory Syndrome CoronaVirus 2 (SARS-CoV2) has been identified in Wuhan, China, which causes severe pulmonary complications and flu syndrome, which has spread rapidly to all continents.
- Conditions
- Coronavirus Infections, SARS-CoV 2, SARS (Severe Acute Respiratory Syndrome), Pulmonary Disease
- Trial name
- NCT04361461
- Testing
- Hydroxychloroquine Sulfate, Hydroxychloroquine Sulfate + Azythromycin
- Where
- Brazil
- Sponsor
- Apsen Farmaceutica S.A.
Healthy Participants
Food Effect Study to Evaluate the Effect of High-Fat Meal on the Relative Bioavailability of PF-07321332 Boosted With Ritonavir in Healthy Adult Participants
This is a Phase 1, open label, single dose, randomized, 2-treatment, 2-sequence, 2-period crossover study to evaluate the effect of high-fat meal on the relative bioavailability of PF-07321332 boosted with ritonavir following…
- Trial name
- NCT05129475
- Testing
- PF-07321332/ritonavir, Ritonavir
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Pfizer
SARS-CoV, SARS-CoV-2
Study of VXCO-100, a SARS-CoV Candidate Vaccine in Healthy Adults in the United States
The purpose of this study is to evaluate the safety and immunogenicity of ascending dose levels of VXCO-100 in healthy adults.
- Trial name
- NCT05870839
- Testing
- VXCO-100
- Where
- 3 sites in United States
- Volunteers
- 121 people, healthy volunteers welcome
- Sponsor
- Vaccine Company, Inc, a wholly owned subsidiary of Eli Lilly and Company
Covid19, SARS-CoV Infection
A Virtual Prospective Study Exploring Activity Trackers and COVID-19 Infections
Prospective, observational, exploratory study exploring the relationship between passively-collected data from wearable activity devices and SARS-CoV-2 infection
- Trial name
- NCT04623138
- Where
- United States
- Volunteers
- 847 people, healthy volunteers welcome
- Sponsor
- Evidation Health